Table S4. TCOF1 Related Genes Calculated by Genedeck Database

Total Page:16

File Type:pdf, Size:1020Kb

Table S4. TCOF1 Related Genes Calculated by Genedeck Database Table S4. TCOF1 related genes calculated by Genedeck database involved in different biological process analysed by DAVID database List Pop Pop Fold Term P Value Genes Bonferroni Benjamini FDR Total Hits Total Enrichment GO:0010604~positive regulation of 1.67E-70 MEF2C, HRAS, THRB, STAT5A, STAT5B, SNCA, TGFB3, CASK, TLR4, TBP, CBFB, TGFB1, ZIC3, 481 857 13528 5.119556 6.48E-67 6.48E-67 3.09E-67 macromolecule metabolic process CITED2, TGFB2, APOE, GATA4, H2AFX, RARB, MLL4, CCNA2, INSR, SYK, RARG, MYO6, RXRA, PPARGC1A, IRS1, HES1, HHEX, MAPK1, EP300, HES5, JUN, SIX1, VEGFA, MAPK9, CAV1, BLM, SOX4 GO:0042127~regulation of cell 1.90E-68 NOG, HRAS, IL18, STAT5A, PTGS1, STAT5B, TGFB3, IL13, FGF10, TGFB1, TGFB2, BDNF, MYD88, 481 787 13528 5.289024 7.37E-65 3.69E-65 3.51E-65 proliferation CDKN2A, CDKN2C, APOE, CDKN2D, ILK, GATA4, RARB, CCNA2, INSR, SYK, EGFR, GTPBP4, RARG, RXRA, EFNB1, IRS1, HES1, PTHLH, HHEX, MAPK1, FGFR1OP, JUN, VEGFA, FOXG1, PDGFRB, F GO:0009891~positive regulation of 1.85E-66 MEF2C, HRAS, THRB, STAT5A, STAT5B, TGFB3, CASK, TLR4, TBP, TGFB1, ZIC3, CBFB, CITED2, 481 695 13528 5.584481 7.20E-63 2.40E-63 3.43E-63 biosynthetic process TGFB2, APOE, GATA4, RARB, MLL4, CCNA2, INSR, SYK, EGFR, RARG, MYO6, RXRA, PPARGC1A, IRS1, HES1, PTHLH, HHEX, MAPK1, EP300, HES5, JUN, SIX1, VEGFA, BLM, SOX4, ABCA1, SOX9 GO:0031328~positive regulation of 2.16E-65 MEF2C, HRAS, THRB, STAT5A, STAT5B, TGFB3, CASK, TLR4, TBP, TGFB1, ZIC3, CBFB, CITED2, 481 685 13528 5.58389 8.40E-62 2.10E-62 4.00E-62 cellular biosynthetic process APOE, GATA4, RARB, MLL4, CCNA2, INSR, SYK, EGFR, RARG, MYO6, RXRA, PPARGC1A, IRS1, HES1, PTHLH, HHEX, MAPK1, EP300, HES5, JUN, SIX1, VEGFA, BLM, SOX4, ABCA1, SOX9, SRF, GO:0051173~positive regulation of 4.29E-64 MEF2C, HRAS, THRB, STAT5A, STAT5B, TGFB3, CASK, TBP, TGFB1, ZIC3, CBFB, CITED2, APOE, 481 644 13528 5.721026 1.67E-60 3.34E-61 7.95E-61 nitrogen compound metabolic process GATA4, H2AFX, RARB, MLL4, CCNA2, INSR, EGFR, RARG, MYO6, RXRA, PPARGC1A, PTHLH, HES1, HHEX, MAPK1, EP300, HES5, JUN, SIX1, VEGFA, BLM, SOX4, ABCA1, SOX9, SRF, WT1, ARNT, GO:0010557~positive regulation of 3.04E-63 MEF2C, HRAS, THRB, STAT5A, STAT5B, TGFB3, CASK, TBP, TLR4, TGFB1, ZIC3, CBFB, CITED2, 481 654 13528 5.633549 1.18E-59 1.97E-60 5.63E-60 macromolecule biosynthetic process TGFB2, GATA4, RARB, MLL4, CCNA2, INSR, SYK, RARG, MYO6, RXRA, PPARGC1A, IRS1, HES1, HHEX, MAPK1, EP300, HES5, JUN, SIX1, VEGFA, BLM, SOX4, SOX9, SRF, WT1, ARNT, NR1H2, H GO:0045935~positive regulation of 6.05E-63 MEF2C, HRAS, THRB, STAT5A, STAT5B, TGFB3, CASK, TBP, TGFB1, ZIC3, CBFB, CITED2, APOE, 481 624 13528 5.769177 2.35E-59 3.36E-60 1.12E-59 nucleobase, nucleoside, nucleotide and GATA4, H2AFX, RARB, MLL4, INSR, CCNA2, RARG, MYO6, RXRA, PPARGC1A, PTHLH, HES1, nucleic acid metabolic process HHEX, MAPK1, EP300, HES5, JUN, SIX1, VEGFA, BLM, SOX4, ABCA1, SOX9, SRF, WT1, ARNT, NR1H2 GO:0010941~regulation of cell death 1.08E-62 MEF2C, XRCC5, HRAS, MAEA, MMP9, STAT5A, STAT5B, SNCA, TGFB3, TLR4, TGFB1, BTK, 481 815 13528 4.969279 4.20E-59 5.25E-60 2.00E-59 CITED2, TGFB2, MAP3K7, BDNF, MYD88, CDKN2A, CD44, HTRA2, CDKN2C, APOE, CDKN2D, ILK, RARB, FAS, TWIST2, EGFR, RARG, RXRA, FADD, STK4, MAPK1, JUN, VEGFA, RIPK3, MAPK9, MAPK8, TNF GO:0043067~regulation of programmed 5.13E-62 MEF2C, XRCC5, HRAS, MAEA, MMP9, STAT5A, SNCA, STAT5B, TGFB3, TLR4, TGFB1, BTK, 481 812 13528 4.953002 1.99E-58 2.21E-59 9.49E-59 cell death CITED2, TGFB2, MAP3K7, BDNF, MYD88, CDKN2A, CD44, HTRA2, CDKN2C, APOE, CDKN2D, ILK, RARB, FAS, TWIST2, EGFR, RARG, RXRA, FADD, STK4, MAPK1, JUN, VEGFA, RIPK3, MAPK9, MAPK8, TNF GO:0010628~positive regulation of gene 5.98E-61 MEF2C, THRB, STAT5A, STAT5B, TGFB3, CASK, TBP, TGFB1, ZIC3, CBFB, CITED2, GATA4, 481 581 13528 5.905711 2.32E-57 2.32E-58 1.11E-57 expression RARB, CCNA2, MLL4, MYO6, RARG, RXRA, PPARGC1A, HES1, HHEX, MAPK1, EP300, HES5, JUN, SIX1, VEGFA, MAPK9, BLM, SOX4, SOX9, SRF, WT1, ARNT, NR1H2, HOXA1, HOXA2, NKX2-1, RUNX1, R GO:0045944~positive regulation of 4.66E-59 MEF2C, THRB, STAT5A, STAT5B, TGFB3, CASK, ZIC3, TGFB1, CBFB, CITED2, GATA4, RARB, 481 371 13528 7.504985 1.81E-55 1.65E-56 8.63E-56 transcription from RNA polymerase II MYO6, RARG, RXRA, PPARGC1A, HES1, HHEX, EP300, HES5, JUN, SIX1, VEGFA, SOX9, SRF, promoter WT1, ARNT, NR1H2, HOXA1, HOXA2, NKX2-1, RUNX1, RUNX2, NKX2-5, BMP4, BMP2, MLL, MAFB, GRIN1, GO:0042981~regulation of apoptosis 4.74E-59 MEF2C, XRCC5, HRAS, MAEA, MMP9, STAT5A, SNCA, STAT5B, TGFB3, TLR4, TGFB1, BTK, 481 804 13528 4.862362 1.84E-55 1.54E-56 8.78E-56 CITED2, TGFB2, MAP3K7, BDNF, MYD88, CDKN2A, CD44, HTRA2, CDKN2C, APOE, CDKN2D, ILK, RARB, FAS, TWIST2, EGFR, RARG, RXRA, FADD, STK4, MAPK1, JUN, VEGFA, RIPK3, MAPK9, MAPK8, TNF GO:0045941~positive regulation of 1.18E-57 MEF2C, THRB, STAT5A, STAT5B, TGFB3, CASK, TBP, TGFB1, ZIC3, CBFB, CITED2, GATA4, 481 564 13528 5.834388 4.59E-54 3.53E-55 2.19E-54 transcription RARB, CCNA2, MLL4, MYO6, RARG, RXRA, PPARGC1A, HES1, HHEX, MAPK1, EP300, HES5, JUN, SIX1, VEGFA, BLM, SOX4, SOX9, SRF, WT1, ARNT, NR1H2, HOXA1, HOXA2, NKX2-1, RUNX1, RUNX2, N GO:0045893~positive regulation of 6.12E-56 MEF2C, THRB, STAT5A, STAT5B, TGFB3, CASK, ZIC3, TGFB1, CBFB, CITED2, GATA4, RARB, 481 477 13528 6.308904 2.38E-52 1.70E-53 1.13E-52 transcription, DNA-dependent MLL4, MYO6, RARG, RXRA, PPARGC1A, HES1, HHEX, EP300, HES5, JUN, SIX1, VEGFA, SOX4, SOX9, SRF, WT1, ARNT, NR1H2, HOXA1, HOXA2, NKX2-1, RUNX1, RUNX2, NKX2-5, BMP4, BMP2, MLL, GO:0051254~positive regulation of RNA 1.48E-55 MEF2C, THRB, STAT5A, STAT5B, TGFB3, CASK, ZIC3, TGFB1, CBFB, CITED2, GATA4, RARB, 481 481 13528 6.256439 5.75E-52 3.83E-53 2.74E-52 metabolic process MLL4, MYO6, RARG, RXRA, PPARGC1A, HES1, HHEX, EP300, HES5, JUN, SIX1, VEGFA, SOX4, SOX9, SRF, WT1, ARNT, NR1H2, HOXA1, HOXA2, NKX2-1, RUNX1, RUNX2, NKX2-5, BMP4, BMP2, MLL, GO:0006357~regulation of transcription 7.08E-49 MEF2C, THRB, STAT5A, STAT5B, FST, TGFB3, CASK, TGFB1, ZIC3, CBFB, CITED2, GATA1, 481 727 13528 4.681009 2.75E-45 1.72E-46 1.31E-45 from RNA polymerase II promoter GATA4, RARB, TWIST2, IKBKAP, MYO6, RARG, RXRA, RBL1, PPARGC1A, HES1, HHEX, EP300, HES5, JUN, SIX1, VEGFA, MNX1, TFAP2A, SOX9, SRF, WT1, ARNT, NR1H2, VDR, HOXA1, TAL1, HOXA2, GO:0051094~positive regulation of 1.05E-46 XRCC5, THRB, FOXA2, STAT5A, PPARG, STAT5B, FST, PAX6, TGFB3, NFKB1, GLI2, GLI3, 481 278 13528 7.789946 4.09E-43 2.41E-44 1.95E-43 developmental process TGFB1, TGFB2, AKT1, MEN1, ACVR1B, CCNE1, BDNF, ILK, GATA4, RARA, NOS3, NRG1, INSR, FGF2, SYK, LYN, DLL3, RB1, ACVR2A, CD36, JUN, FOXG1, MAPK9, NGFR, ACVR1, TNF, DRD2, CSF1, KI GO:0008284~positive regulation of cell 1.66E-43 NOG, NBN, HRAS, STAT5A, IL18, STAT5B, PAX6, IL13, FGF10, TP63, PAX3, GLI2, TGFB1, TGFB2, 481 414 13528 5.978206 6.45E-40 3.58E-41 3.08E-40 proliferation ILK, TGFA, NRG1, INSR, FGF2, MYC, CCNA2, SYK, EGFR, CDC7, LYN, CCKBR, EFNB1, CDK6, IRS1, CDK2, PTHLH, HES1, MAPK1, PRKCQ, CCND1, HIPK1, FGFR1OP, JUN, HIPK2, FOXG1, VE GO:0045597~positive regulation of cell 3.11E-43 XRCC5, THRB, FOXA2, STAT5A, PPARG, STAT5B, PAX6, TGFB3, NFKB1, GLI2, GLI3, TGFB1, 481 229 13528 8.351451 1.21E-39 6.35E-41 5.75E-40 differentiation TGFB2, AKT1, MEN1, ACVR1B, CCNE1, BDNF, ILK, RARA, NRG1, FGF2, SYK, LYN, DLL3, RB1, ACVR2A, CD36, JUN, FOXG1, MAPK9, NGFR, ACVR1, DRD2, CSF1, KITLG, KIT, SRF, ADA, ARNT, EPH GO:0043069~negative regulation of 6.57E-43 XRCC5, MEF2C, HRAS, MAEA, STAT5A, SNCA, STAT5B, TGFB3, TP63, NFKB1, PAX2, PTEN, 481 359 13528 6.424035 2.56E-39 1.28E-40 1.22E-39 programmed cell death CITED2, AKT1, MAP3K7, EDNRB, BDNF, MYD88, APOE, CDKN2D, PAX7, ILK, NOS3, FAS, NRG1, MKL1, CASP2, MYC, TERT, TWIST2, EGFR, CDK1, ESR1, TP53, ESR2, EYA1, PSEN1, HIPK2, PSEN2, VE GO:0060548~negative regulation of cell 8.23E-43 XRCC5, MEF2C, HRAS, MAEA, STAT5A, SNCA, STAT5B, TGFB3, TP63, NFKB1, PAX2, PTEN, 481 360 13528 6.406191 3.20E-39 1.52E-40 1.52E-39 death CITED2, AKT1, MAP3K7, EDNRB, BDNF, MYD88, APOE, CDKN2D, PAX7, ILK, NOS3, FAS, NRG1, MKL1, CASP2, MYC, TERT, TWIST2, EGFR, CDK1, ESR1, TP53, ESR2, EYA1, PSEN1, HIPK2, PSEN2, VE GO:0043066~negative regulation of 1.68E-40 XRCC5, MEF2C, HRAS, MAEA, STAT5A, SNCA, STAT5B, TGFB3, TP63, NFKB1, PTEN, CITED2, 481 354 13528 6.276425 6.55E-37 2.98E-38 3.12E-37 apoptosis AKT1, MAP3K7, EDNRB, BDNF, MYD88, APOE, CDKN2D, PAX7, ILK, NOS3, FAS, MKL1, NRG1, CASP2, MYC, TERT, TWIST2, EGFR, CDK1, ESR1, TP53, ESR2, EYA1, PSEN1, HIPK2, PSEN2, VEGFA, A GO:0006468~protein amino acid 1.81E-40 STAT5A, TGFB3, CASK, TGFB1, BTK, TGFB2, CSNK2A2, MAP3K7, CSNK2A1, COL4A3BP, ILK, 481 667 13528 4.469599 7.05E-37 3.07E-38 3.36E-37 phosphorylation PRKACA, INSR, MAP2K7, SYK, EGFR, IKBKAP, RET, STK4, MAPK1, CAMK4, RIPK3, PDGFRB, ROR2, MAPK9, MAPK8, MAPK7, EIF2AK3, FGFR2, FGFR1, ERBB4, STK11, ERBB3, ERBB2, NEK1, HUS1, MAP GO:0035295~tube development 5.00E-40 NOG, FOXA2, TGFB3, TP63, FGF10, PAX3, PAX2, GLI2, GLI3, ZIC3, MAP3K7, BDNF, CD44, CTGF, 481 220 13528 8.181743 1.94E-36 8.09E-38 9.25E-37 CXCR4, ILK, GATA4, CASP8, MKKS, NOS3, HHIP, RARB, FGF2, RET, MMP14, HES1, PTHLH, HHEX, EYA1, EP300, PSEN1, PSEN2, VEGFA, SIX1, FOXC2, TFAP2A, FOXC1, MED1, ACVR1, WNT5A GO:0007389~pattern specification process 1.40E-39 NOG, FOXA2, FST, PAX6, TP63, FGF10, ZEB1, GLI2, GLI3, ZIC3, CITED2, CXCR4, PAX7, GATA4, 481 267 13528 7.268191 5.44E-36 2.17E-37 2.59E-36 MKKS, HHIP, PITX2, EGR2, GSC, EFNB1, DLL3, LEF1, HES1, CTNNBIP1, ACVR2A, HHEX, EYA1, CRKL, EP300, PSEN1, HIPK1, HOXC13, HIPK2, PSEN2, FOXG1, VEGFA, SIX1, MNX1, ROR2, F GO:0010033~response to organic 1.45E-36 STAT5A, SLC6A3, PTGS1, SNCA, STAT5B, TGFB3, TLR4, AQP1, TGFB1, TGFB2, MYD88, CD44, 481 721
Recommended publications
  • A Reciprocal Effort Towards Better Approaches for Drug Discovery
    Acta Pharmacologica Sinica (2013) 34: 765–776 npg © 2013 CPS and SIMM All rights reserved 1671-4083/13 $32.00 www.nature.com/aps Review iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery Ru ZHANG1, Li-hong ZHANG2, Xin XIE1, 2, * 1Laboratory of Receptor-based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China; 2CAS Key Laboratory of Receptor Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China The revolutionary induced pluripotent stem cell (iPSC) technology provides a new path for cell replacement therapies and drug screen- ing. Patient-specific iPSCs and subsequent differentiated cells manifesting disease phenotypes will finally position human disease pathology at the core of drug discovery. Cells used to test the toxic effects of drugs can also be generated from normal iPSCs and pro- vide a much more accurate and cost-effective system than many animal models. Here, we highlight the recent progress in iPSC-based cell therapy, disease modeling and drug evaluations. In addition, we discuss the use of small molecule drugs to improve the genera- tion of iPSCs and understand the reprogramming mechanism. It is foreseeable that the interplay between iPSC technology and small molecule compounds will push forward the applications of iPSC-based therapy and screening systems in the real world and eventually revolutionize the methods used to treat diseases. Keywords: induced pluripotent stem cells (iPSCs); disease modeling; drug screening; toxicity evaluation; cell replacement therapy; small molecules; drug development Acta Pharmacologica Sinica (2013) 34: 765–776; doi: 10.1038/aps.2013.21; published online 22 Apr 2013 Introduction his/her own iPSCs[1–3].
    [Show full text]
  • Core Transcriptional Regulatory Circuitries in Cancer
    Oncogene (2020) 39:6633–6646 https://doi.org/10.1038/s41388-020-01459-w REVIEW ARTICLE Core transcriptional regulatory circuitries in cancer 1 1,2,3 1 2 1,4,5 Ye Chen ● Liang Xu ● Ruby Yu-Tong Lin ● Markus Müschen ● H. Phillip Koeffler Received: 14 June 2020 / Revised: 30 August 2020 / Accepted: 4 September 2020 / Published online: 17 September 2020 © The Author(s) 2020. This article is published with open access Abstract Transcription factors (TFs) coordinate the on-and-off states of gene expression typically in a combinatorial fashion. Studies from embryonic stem cells and other cell types have revealed that a clique of self-regulated core TFs control cell identity and cell state. These core TFs form interconnected feed-forward transcriptional loops to establish and reinforce the cell-type- specific gene-expression program; the ensemble of core TFs and their regulatory loops constitutes core transcriptional regulatory circuitry (CRC). Here, we summarize recent progress in computational reconstitution and biologic exploration of CRCs across various human malignancies, and consolidate the strategy and methodology for CRC discovery. We also discuss the genetic basis and therapeutic vulnerability of CRC, and highlight new frontiers and future efforts for the study of CRC in cancer. Knowledge of CRC in cancer is fundamental to understanding cancer-specific transcriptional addiction, and should provide important insight to both pathobiology and therapeutics. 1234567890();,: 1234567890();,: Introduction genes. Till now, one critical goal in biology remains to understand the composition and hierarchy of transcriptional Transcriptional regulation is one of the fundamental mole- regulatory network in each specified cell type/lineage.
    [Show full text]
  • Significant Shortest Paths for the Detection of Putative Disease Modules
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.01.019844; this version posted April 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. SIGNIFICANT SHORTEST PATHS FOR THE DETECTION OF PUTATIVE DISEASE MODULES Daniele Pepe1 1Department of Oncology, KU Leuven, LKI–Leuven Cancer Institute, Leuven, Belgium Email address: DP: danielepepe84@gmail.com bioRxiv preprint doi: https://doi.org/10.1101/2020.04.01.019844; this version posted April 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Keywords Structural equation modeling, significant shortest paths, pathway analysis, disease modules. Abstract Background The characterization of diseases in terms of perturbated gene modules was recently introduced for the analysis of gene expression data. Some approaches were proposed in literature, but many times they are inductive approaches. This means that starting directly from data, they try to infer key gene networks potentially associated to the biological phenomenon studied. However they ignore the biological information already available to characterize the gene modules. Here we propose the detection of perturbed gene modules using the combination of data driven and hypothesis-driven approaches relying on biological metabolic pathways and significant shortest paths tested by structural equation modeling.
    [Show full text]
  • Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin
    cells Review Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin Agnieszka Bochy ´nska,Juliane Lüscher-Firzlaff and Bernhard Lüscher * ID Institute of Biochemistry and Molecular Biology, Medical School, RWTH Aachen University, Pauwelsstrasse 30, 52057 Aachen, Germany; abochynska@ukaachen.de (A.B.); jluescher-firzlaff@ukaachen.de (J.L.-F.) * Correspondence: luescher@rwth-aachen.de; Tel.: +49-241-8088850; Fax: +49-241-8082427 Received: 18 January 2018; Accepted: 27 February 2018; Published: 2 March 2018 Abstract: Regulation of gene expression is achieved by sequence-specific transcriptional regulators, which convey the information that is contained in the sequence of DNA into RNA polymerase activity. This is achieved by the recruitment of transcriptional co-factors. One of the consequences of co-factor recruitment is the control of specific properties of nucleosomes, the basic units of chromatin, and their protein components, the core histones. The main principles are to regulate the position and the characteristics of nucleosomes. The latter includes modulating the composition of core histones and their variants that are integrated into nucleosomes, and the post-translational modification of these histones referred to as histone marks. One of these marks is the methylation of lysine 4 of the core histone H3 (H3K4). While mono-methylation of H3K4 (H3K4me1) is located preferentially at active enhancers, tri-methylation (H3K4me3) is a mark found at open and potentially active promoters. Thus, H3K4 methylation is typically associated with gene transcription. The class 2 lysine methyltransferases (KMTs) are the main enzymes that methylate H3K4. KMT2 enzymes function in complexes that contain a necessary core complex composed of WDR5, RBBP5, ASH2L, and DPY30, the so-called WRAD complex.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD (cevansmo@iu.edu) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Estrogen-Related Receptor Alpha: an Under-Appreciated Potential Target for the Treatment of Metabolic Diseases
    International Journal of Molecular Sciences Review Estrogen-Related Receptor Alpha: An Under-Appreciated Potential Target for the Treatment of Metabolic Diseases Madhulika Tripathi, Paul Michael Yen and Brijesh Kumar Singh * Laboratory of Hormonal Regulation, Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, Singapore 169857, Singapore; madhulika.tripathi@duke-nus.edu.sg (M.T.); paul.yen@duke-nus.edu.sg (P.M.Y.) * Correspondence: singhbrijeshk@duke-nus.edu.sg Received: 7 February 2020; Accepted: 24 February 2020; Published: 28 February 2020 Abstract: The estrogen-related receptor alpha (ESRRA) is an orphan nuclear receptor (NR) that significantly influences cellular metabolism. ESRRA is predominantly expressed in metabolically-active tissues and regulates the transcription of metabolic genes, including those involved in mitochondrial turnover and autophagy. Although ESRRA activity is well-characterized in several types of cancer, recent reports suggest that it also has an important role in metabolic diseases. This minireview focuses on the regulation of cellular metabolism and function by ESRRA and its potential as a target for the treatment of metabolic disorders. Keywords: estrogen-related receptor alpha; mitophagy; mitochondrial turnover; metabolic diseases; non-alcoholic fatty liver disease (NAFLD); adipogenesis; adaptive thermogenesis 1. Introduction When the estrogen-related receptor alpha (ESRRA) was first cloned, it was found to be a nuclear receptor (NR) that had DNA sequence homology to the estrogen receptor alpha (ESR1) [1]. There are several examples of estrogen-related receptor (ESRR) and estrogen-signaling cross-talk via mutual transcriptional regulation or reciprocal binding to each other’s response elements of common target genes in a context-specific manner [2,3].
    [Show full text]
  • 32-3099: PRKAB1 Recombinant Protein Description
    9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: info@abeomics.com 32-3099: PRKAB1 Recombinant Protein Alternative Name : AMPK,HAMPKb,5'-AMP-activated protein kinase subunit beta-1,AMPK subunit beta-1,AMPKb,PRKAB1. Description Source : E.coli. PRKAB1 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 293 amino acids (1-270 a.a.) and having a molecular mass of 32.8 kDa. The PRKAB1 is fused to a 23 amino acid His Tag at N- Terminus and purified by proprietary chromatographic techniques. 5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) hinders protein, carbohydrate and lipid biosynthesis, in addition to cell growth and proliferation. AMPK is a heterotrimer comprised of an alpha catalytic subunit, and non-catalytic beta and gamma subunits. AMPK acts via direct phosphorylation of metabolic enzymes, and longer-term effects by phosphorylation of transcription regulators. PRKAB1 is a regulator of cellular polarity by remodeling the actin cytoskeleton; most likely by indirectly activating myosin. Beta non-catalytic subunit acts as a scaffold on which the AMPK complex compiles, through its C-terminus that joins alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1, PRKAG2 or PRKAG3). Product Info Amount : 5 µg Purification : Greater than 85% as determined by SDS-PAGE. The PRKAB1 protein solution (0.5mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.15M NaCl, Content : 10% glycerol and 1mM DTT. Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of Storage condition : time.
    [Show full text]
  • NBN Gene Analysis and It's Impact on Breast Cancer
    Journal of Medical Systems (2019) 43: 270 https://doi.org/10.1007/s10916-019-1328-z IMAGE & SIGNAL PROCESSING NBN Gene Analysis and it’s Impact on Breast Cancer P. Nithya1 & A. ChandraSekar1 Received: 8 March 2019 /Accepted: 7 May 2019 /Published online: 5 July 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Single Nucleotide Polymorphism (SNP) researches have become essential in finding out the congenital relationship of structural deviations with quantitative traits, heritable diseases and physical responsiveness to different medicines. NBN is a protein coding gene (Breast Cancer); Nibrin is used to fix and rebuild the body from damages caused because of strand breaks (both singular and double) associated with protein nibrin. NBN gene was retrieved from dbSNP/NCBI database and investigated using computational SNP analysis tools. The encrypted region in SNPs (exonal SNPs) were analyzed using software tools, SIFT, Provean, Polyphen, INPS, SNAP and Phd-SNP. The 3’ends of SNPs in un-translated region were also investigated to determine the impact of binding. The association of NBN gene polymorphism leads to several diseases was studied. Four SNPs were predicted to be highly damaged in coding regions which are responsible for the diseases such as, Aplastic Anemia, Nijmegan breakage syndrome, Microsephaly normal intelligence, immune deficiency and hereditary cancer predisposing syndrome (clivar). The present study will be helpful in finding the suitable drugs in future for various diseases especially for breast cancer. Keywords NBN . Single nucleotide polymorphism . Double strand breaks . nsSNP . Associated diseases Introduction NBN has a more complex structure due to its interaction with large proteins formed from the ATM gene which is NBN (Nibrin) is a protein coding gene, it is also known as highly essential in identifying damaged strands of DNA NBS1, Cell cycle regulatory Protein P95, is situated on and facilitating their repair [1].
    [Show full text]
  • Utx Is Required for Proper Induction of Ectoderm and Mesoderm During Differentiation of Embryonic Stem Cells
    Utx Is Required for Proper Induction of Ectoderm and Mesoderm during Differentiation of Embryonic Stem Cells Cristina Morales Torres1,2, Anne Laugesen1,2, Kristian Helin1,2,3* 1 Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark, 2 Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark, 3 The Danish Stem Cell Center, University of Copenhagen, Copenhagen, Denmark Abstract Embryonic development requires chromatin remodeling for dynamic regulation of gene expression patterns to ensure silencing of pluripotent transcription factors and activation of developmental regulators. Demethylation of H3K27me3 by the histone demethylases Utx and Jmjd3 is important for the activation of lineage choice genes in response to developmental signals. To further understand the function of Utx in pluripotency and differentiation we generated Utx knockout embryonic stem cells (ESCs). Here we show that Utx is not required for the proliferation of ESCs, however, Utx contributes to the establishment of ectoderm and mesoderm in vitro. Interestingly, this contribution is independent of the catalytic activity of Utx. Furthermore, we provide data showing that the Utx homologue, Uty, which is devoid of detectable demethylase activity, and Jmjd3 partly compensate for the loss of Utx. Taken together our results show that Utx is required for proper formation of ectoderm and mesoderm in vitro, and that Utx, similar to its C.elegans homologue, has demethylase dependent and independent functions. Citation: Morales Torres C, Laugesen A, Helin K (2013) Utx Is Required for Proper Induction of Ectoderm and Mesoderm during Differentiation of Embryonic Stem Cells. PLoS ONE 8(4): e60020. doi:10.1371/journal.pone.0060020 Editor: Qiang Wu, National University of Singapore, Singapore Received December 13, 2012; Accepted February 21, 2013; Published April 3, 2013 Copyright: ß 2013 Morales Torres et al.
    [Show full text]
  • Proteomics Provides Insights Into the Inhibition of Chinese Hamster V79
    www.nature.com/scientificreports OPEN Proteomics provides insights into the inhibition of Chinese hamster V79 cell proliferation in the deep underground environment Jifeng Liu1,2, Tengfei Ma1,2, Mingzhong Gao3, Yilin Liu4, Jun Liu1, Shichao Wang2, Yike Xie2, Ling Wang2, Juan Cheng2, Shixi Liu1*, Jian Zou1,2*, Jiang Wu2, Weimin Li2 & Heping Xie2,3,5 As resources in the shallow depths of the earth exhausted, people will spend extended periods of time in the deep underground space. However, little is known about the deep underground environment afecting the health of organisms. Hence, we established both deep underground laboratory (DUGL) and above ground laboratory (AGL) to investigate the efect of environmental factors on organisms. Six environmental parameters were monitored in the DUGL and AGL. Growth curves were recorded and tandem mass tag (TMT) proteomics analysis were performed to explore the proliferative ability and diferentially abundant proteins (DAPs) in V79 cells (a cell line widely used in biological study in DUGLs) cultured in the DUGL and AGL. Parallel Reaction Monitoring was conducted to verify the TMT results. γ ray dose rate showed the most detectable diference between the two laboratories, whereby γ ray dose rate was signifcantly lower in the DUGL compared to the AGL. V79 cell proliferation was slower in the DUGL. Quantitative proteomics detected 980 DAPs (absolute fold change ≥ 1.2, p < 0.05) between V79 cells cultured in the DUGL and AGL. Of these, 576 proteins were up-regulated and 404 proteins were down-regulated in V79 cells cultured in the DUGL. KEGG pathway analysis revealed that seven pathways (e.g.
    [Show full text]
  • N-Glycan Trimming in the ER and Calnexin/Calreticulin Cycle
    Neurotransmitter receptorsGABA and A postsynapticreceptor activation signal transmission Ligand-gated ion channel transport GABAGABA Areceptor receptor alpha-5 alpha-1/beta-1/gamma-2 subunit GABA A receptor alpha-2/beta-2/gamma-2GABA receptor alpha-4 subunit GABAGABA receptor A receptor beta-3 subunitalpha-6/beta-2/gamma-2 GABA-AGABA receptor; A receptor alpha-1/beta-2/gamma-2GABA receptoralpha-3/beta-2/gamma-2 alpha-3 subunit GABA-A GABAreceptor; receptor benzodiazepine alpha-6 subunit site GABA-AGABA-A receptor; receptor; GABA-A anion site channel (alpha1/beta2 interface) GABA-A receptor;GABA alpha-6/beta-3/gamma-2 receptor beta-2 subunit GABAGABA receptorGABA-A receptor alpha-2receptor; alpha-1 subunit agonist subunit GABA site Serotonin 3a (5-HT3a) receptor GABA receptorGABA-C rho-1 subunitreceptor GlycineSerotonin receptor subunit3 (5-HT3) alpha-1 receptor GABA receptor rho-2 subunit GlycineGlycine receptor receptor subunit subunit alpha-2 alpha-3 Ca2+ activated K+ channels Metabolism of ingested SeMet, Sec, MeSec into H2Se SmallIntermediateSmall conductance conductance conductance calcium-activated calcium-activated calcium-activated potassium potassium potassiumchannel channel protein channel protein 2 protein 1 4 Small conductance calcium-activatedCalcium-activated potassium potassium channel alpha/beta channel 1 protein 3 Calcium-activated potassiumHistamine channel subunit alpha-1 N-methyltransferase Neuraminidase Pyrimidine biosynthesis Nicotinamide N-methyltransferase Adenosylhomocysteinase PolymerasePolymeraseHistidine basic
    [Show full text]
  • Product Sheet CG1021
    ATM Antibody Applications: WB, IF Detected MW: 350 kDa Cat. No. CG1021 Species & Reactivity: Human, Mouse Isotype: Rabbit IgG BACKGROUND APPLICATIONS ATM (Ataxia telangiectasia mutated) and ATR Application: *Dilution: (Ataxia telangiectasia and Rad3 related) are WB 1:500-1,000 closely related kinases that are activated by DNA IP n/d damage. These serine-threonine protein kinases IHC n/d are part of the phosphatidylinositol-3 kinase-like ICC n/d kinase (PIKK) family. Upon recruitment by the DNA damage binding proteins/complexes (ATRIP FACS n/d for ATR; MRN for ATM), ATM/ATR initiate the DNA IF 1:100-1:200 damage checkpoint by phosphorylating a number *Optimal dilutions must be determined by end user. of key proteins. Once activated, the checkpoint leads to cell cycle arrest and either DNA repair or apoptosis. ATM is activated by double stranded QUALITY CONTROL DATA breaks and phosphorylates Chk2, whilst ATR is activated by single strand breaks and phosphorylates Chk1.1 ATM activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. It recognizes the substrate consensus sequence [ST]-Q and phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism.2 ATM functions as a regulator of a wide variety of downstream proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1. Both ATM and ATR are thought to be master controllers of cell cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability.3 Mutations in ATM gene are associated with ataxia telangiectasia, an autosomal recessive disorder.
    [Show full text]